BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MISSISSAUGA, Ontario, Nov. 10, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2022 on Wednesday, November 16, 2022 after market hours. A presentation on the Company’s third quarter and first nine months 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 12,109,761 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Staff

Recent Posts

TE Connectivity declares quarterly dividend

GALWAY, Ireland, June 11, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL) announced today that…

9 hours ago

SRM Equity Partners Acquires RF Technologies, a Leader in Safety and Security Solutions for Healthcare and Senior Living

BROOKFIELD, Wis., June 11, 2025 /PRNewswire/ -- SRM Equity Partners ("SRM"), an operationally focused private…

9 hours ago

New Findings from NSC Grant Recipients Help Tackle America’s Most Common Workplace Injury

MSD Solutions Lab programs unite academic researchers and industry partners to drive innovation WASHINGTON, June…

9 hours ago

Version 3.0 AI Automation Platform Launches at VGM’s Heartland Conference

Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without…

9 hours ago

AllSci Wins Grant to Expand AI Platform for Pharma and Biotech R&D: Accelerating Hypothesis-Driven Discovery

Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science…

9 hours ago

RIVANNA selected for prestigious MedTech Innovator 2025 Accelerator Cohort

— One of 65 startups chosen from nearly 1,500 global applicants — — Selected to…

9 hours ago